• linkedin
  • Increase Font
  • Sharebar

    Immune content linked to aggressive PCa outcomes


    Interestingly, the immune content score was prognostic primarily in patients that received post-op radiation, according to the researchers.

    “Radiation has been hypothesized to interact with the immune system, and there are multiple ongoing studies investigating this relationship clinically with immunotherapies,” Dr. Zhao said. “Therefore, this finding is particularly intriguing and warrants further investigation.”

    Dr. Zhao and co-authors also looked at the interaction between immune and tumor cells, finding, for example, that higher levels of T-cells and macrophages were prognostic for worse distant metastasis-free survival (p<.05).

    Read: Prostate Ca study reveals more evidence of racial disparity

    PD-L1 in this study was not associated with outcomes. In contrast, PD-L2—a ligand that is also a binding partner of the PD-1 receptor on T-cells—was associated with worse treatment outcomes. Higher levels of PD-L2 were associated with greater likelihood of prostate cancer death (HR=1.45, p=.003), disease recurrence (HR=1.17, p=.013), and distant metastasis (HR=1.25, p=.014).

    “Hopefully, PD-L2 will become a more well-studied target,” Dr. Zhao said in an interview. “Some of the PD-1 inhibitors such as pembrolizumab [KEYTRUDA] and nivolumab [OPDIVO] also theoretically would inhibit the PD-1/PD-L2 interaction.”

    Dr. Zhao has received a research grant from the Prostate Cancer Foundation and travel expenses from GenomeDx Biosciences. Several of his co-authors have a financial or other relationship with one or more pharmaceutical companies.

    More from Urology Times:

    Quality initiative could reduce unnecessary PCa bone scans

    Prostate MRI has value, but results are not ‘gospel’

    Metformin may improve advanced prostate Ca outcomes

    To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.

    Andrew Bowser
    Andrew Bowser is a medical writer based in Brooklyn, New York.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available